<DOC>
	<DOCNO>NCT02135159</DOCNO>
	<brief_summary>The purpose study determine optimal sequence combine trastuzumab emtansine ( T-DM1 ) whole-brain radiotherapy patient present brain metastasis HER2-positive breast cancer term acute toxicity blood/cerebrospinal fluid T-DM1 pharmacokinetics .</brief_summary>
	<brief_title>Patients With Brain Metastases From HER2-positive Breast Cancer</brief_title>
	<detailed_description>Determine best sequence .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>1 . Histologically confirm invasive breast cancer stage IV disease . 2 . HER2 positive primary tumor , define : IHC3+ , IHC2+ ISH positive . 3 . Non operable brain metastasis ( n ≥ 2 ) least one measurable CNS lesion ≥ 10 mm T1weighted gadoliniumenhanced MRI . 4 . No stereotaxie radiotherapy indication 5 . At least two week specific breast cancer treatment ( Trastuzumab , chemotherapy , immunotherapy/biological response modifier , endocrine therapy radiotherapy ) . 6 . Adequate hematologic function ( ANC ≥1x109/L , platelets ≥100 000/L ; Hb &gt; 10g/dL ) , renal function ( creatinine ≤ 1.5x UNL ) hepatic function ( albumin ≥2.5 g/dL ; serum bilirubin ≤1.5x ULN unless due Gilbert 's syndrome ; AST ALT ≤ 5x ULN document liver metastasis ≤ 3x ULN without liver metastasis ) . 7 . At least 18 year old . 8 . ECOG Performance Status 0 2 . 9 . Life expectancy ≥ 3 month . 10 . Potentially reproductive patient must agree use effective contraceptive method treatment , begin 2 week first dose investigational product 28 day final dose investigational product woman . Males able father child must practice adequate method birth control practice complete abstinence intercourse first dose investigational treatment one week final dose investigational treatment . 11 . Women childbearing potential must negative serum pregnancy test within 14 day enrollment and/or urine pregnancy test 48 hour prior administration first study treatment . 12 . Patients must affiliate Social Security System . 13 . Patient information write informed consent form sign . 1 . Previous whole brain radiotherapy ( WBRT ) brain stereotaxie radiotherapy . 2 . Planned concurrent systemic treatment radiation therapy ( corticosteroid , bisphosphonates mannitol ) . 3 . Known contraindication MRI . 4 . Active concurrent malignancy . If history prior malignancy , patient must disease free least 10 year . 5 . Patients concurrent severe and/or uncontrolled medical disease could compromise participation study , : infection , cardiac disease uncontrolled hypertension , congestive cardiac failure , ventricular arrhythmia , active ischemic heart disease , myocardial infarction within one year , LVEF ≤ 50 % , current active hepatic renal disease 6 . Pregnant woman , woman likely become pregnant breastfeeding . 7 . Patients significantly alter mental status prohibit understand study psychological , familial , sociological geographical condition potentially hamper compliance study protocol followup schedule ; condition discuss patient registration trial . 8 . Known hypersensibility component TDM1 9 . Patients receive investigational drug within 30 day prior screen visit . 10 . Individual deprive liberty place authority tutor . 11 . Leptomeningeal metastasis diagnose MRI 12 . Inclusion another protocol within 30 day 13 . Brain metastasis severe intracranial hypertension clinical sign 14 . Other cancer except know primary tumor situ cervix cancer basocellular carcinoma</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>